Researchers performed a protein diffusion network analysis using tissue-specific GRNs to identify predispositions to COVID-19.
T-DM1 reduces long-term risk of death in HER2-positive breast cancer patients
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by
January 16, 2025